NCT06809946

Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy

Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy in Patients With a Pulmonary Lesion Considered to be Malignant - DEFLECT I

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: University Medical Center Groningen · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this feasibility study, bronchoscopy will be combined with fluorescence molecular imaging using the near-infrared fluorescence (NIRF) tracer bevacizumab-800CW for assessment of pulmonary lesions and/or lymph nodes considered to be malignant.

Conditions

• Lung Neoplasms
• Pulmonary Neoplasms
• Lymph Node Involvement
• Pulmonary Nodule

Interventions

Type	Name	Description
DRUG	injection with 15 mg bevacizumab-800CW before bronchoscopy	Patients will receive an intravenous administration of 15 mg bevacizumab-800CW before the bronchoscopy procedure. The bronchoscopy will start with high-definition white light bronchoscopy, followed by fluorescence molecular bronchoscoy to observe the fluorescence signal and MDSFR-SFF spectroscopy to quantify the fluores-cence signal in vivo.
DRUG	injection with 25 mg bevacizumab-800CW before bronchoscopy	Patients will receive an intravenous administration of 15 mg bevacizumab-800CW before the bronchoscopy procedure. The bronchoscopy will start with high-definition white light bronchoscopy, followed by fluorescence molecular bronchoscoy to observe the fluorescence signal and MDSFR-SFF spectroscopy to quantify the fluores-cence signal in vivo.

Timeline

• Start date: 2026-08-17
• Primary completion: 2028-08-17
• Completion: 2028-08-17
• First posted: 2025-02-05
• Last updated: 2026-03-30

Locations

1 site across 1 country: Netherlands